WHITE CITY, Ore., January 18, 2021 (Newswire.com) – Biomed Diagnostics has increased production of the InTray GC®due to the shortages in STI testing supplies. The CDC recommends culture testing in tandem with NAAT testing, due to the dramatic increase in AMR strains of Gonorrhoeae.
The rapid rise in COVID testing, along with projected volume of tests needed monthly, has depleted supplies for other infectious disease testing, primarily sexually transmitted infections. Biomed Diagnostics is responding with a significant increase in production of the InTray GC and the InPouch TV®.
According to the Center for Disease Control and Prevention (CDC), Neisseria Gonorrhoeae poses one of the most urgent threats of antibiotic resistance infections in the United States and the world. COVID is ravaging health care infrastructure, and depleting testing supplies used in STI screening.
The emergence of N. Gonorrhoeae strains resistant to previously effective antibiotics is sounding an alarm throughout the health care community. There is only one class of antibiotics that is currently deemed an effective treatment for this devastating disease.
A 2021 study published by JAMA Pediatrics recommends universal screening for gonococcal infections in adolescents and young adults who used the emergency room for acute care. The rate of Gonorrhea infections is increasing dramatically in the age group 18-22. According to a study in The Lancet, up to two-thirds of N gonorrhoeae infections in women who have oropharyngeal infections, are missed.
For over 10 years, Biomed Diagnostic’s has partnered with STD clinics and health care agencies worldwide in the fight against N. Gonorrhoeae and antimicrobial resistance (AMR). Biomed’s diagnostic test – the InTray GC® – is a prepared selective culture for qualitative detection of oral, rectal and genito-urethral Neisseria gonorrhoeae. It is an essential tool for AMR diagnostics.
The InTray GC is specifically designed for ease-of-use at the point of care and provides visual detection of the microbe. The media is highly selective and specific to gonorrhoeae. The InTray GC, with an embedded C02 tablet, does not require an expensive CO2 incubator, and there are no requirements for replating of the culture for detection. Inoculate the InTray, seal, and observe for microbial growth and color change within 24 hours.
For more information about the InTray GC, please visit https://biomeddiagnostics.com/prepared-culture-media/neisseria-gonorrhoeae or call 800.964.6466.
About Biomed Diagnostics
Biomed Diagnostics, Inc. is a manufacturing company, based in Oregon, USA, and designs and engineers and manufactures prepared culture media devices for the collection, propagation and isolation of pathogenic organisms.
All products are manufactured, tested and validated at Biomed’s secure ISO 13485:2016 compliant, FDA-registered production facility, in Oregon, USA.
Biomed Diagnostics operates in compliance with the Good Manufacturing Practices Regulations (21 CFR, Part 820) for the identified products.
Biomed maintains patents for our packaging systems, as well as possess proprietary formulas for a variety of products. The packaging system along with the media/agar provides unique differentiation in the IVD testing industry.
About Biomed Diagnostics
Biomed Diagnostics COVID testing supplies
Source: Biomed Diagnostics